A1C Almanac

Main Page

Feeding the Microbes That Shrink Your Deepest Fat

Posted

by

dr Karunia Valeriani Japar

Table of Contents
Category:
Tags: , , , ,

Keywords: Adipose Tissue Inflammation, Glucagon-Like Peptide-1 (GLP-1), Gut Microbiome, Insulin Resistance, Precision Nutrition, Resistant Starch, Short-Chain Fatty Acids, Visceral Adiposity

From “Flat Belly” to Visceral Fat Biology

Most people pursue a “flat belly” as a cosmetic goal, yet from a medical standpoint the more relevant target is visceral adiposity. Visceral fat refers to the depot packed deep within the abdominal cavity, wrapped around the liver, pancreas, intestines, and other vital organs, rather than the pinchable subcutaneous fat that sits just under the skin. This compartment is highly vascular, densely innervated, and metabolically active, functioning less like inert storage and more like an inflamed endocrine organ in its own right. Through the secretion of pro‑inflammatory cytokines, adipokines, and excess free fatty acids into the portal circulation, visceral fat perturbs insulin signalling, drives hepatic steatosis, and contributes to atherosclerotic risk even in individuals whose BMI falls within the “normal” range.

Over the past decade, converging human and preclinical data have reframed this visceral depot as part of a broader gut–adipose axis. The intestinal microbiome, once considered a passive passenger, is increasingly recognised as an upstream regulator of both the quantity of visceral fat and its functional “toxicity.” Microbial metabolites, immune interactions, and gut‑derived hormonal signals can promote either adipose inflammation and expansion or, conversely, improved insulin sensitivity and healthier fat distribution. This shifts the clinical question from a narrow focus on “burning more calories” to a more mechanistic inquiry: how can we strategically remodel the gut ecosystem so that it sends “shrink” rather than “store” signals to visceral adipose tissue? Framed this way, interventions that target microbial composition and function become central tools in efforts to reduce high‑risk visceral fat and improve long‑term cardiometabolic health.

Why Visceral Fat is Not “Just More Fat”

Visceral adipose tissue differs from peripheral subcutaneous fat not only in its location but also in its structure and endocrine behaviour. It is highly vascular and densely innervated, and it harbours a rich population of immune cells, rendering it metabolically and immunologically active compared with more inert subcutaneous depots. Because visceral fat drains directly into the portal circulation, it delivers an excess load of free fatty acids, adipokines, and pro‑inflammatory mediators to the liver, where they promote hepatic insulin resistance, triglyceride accumulation (steatosis), and an atherogenic dyslipidaemia profile. This so‑called “portal hypothesis” helps explain why individuals with central obesity and enlarged visceral depots are particularly prone to disturbances in glucose and lipid homeostasis, even when their total body weight or BMI is only modestly elevated [1,2,3,4].

Chronic overnutrition and modern dietary patterns further drive a state of adipose tissue dysfunction, especially within visceral depots. Hypertrophic, stressed adipocytes become insulin‑resistant and more lipolytic, and they undergo cell death, which in turn triggers macrophage recruitment and crown‑like structures that substantially increase local cytokine production and low‑grade inflammation. At the same time, adipokine secretion becomes maladaptive and the tissue’s capacity to safely buffer and store lipids is impaired, promoting ectopic fat deposition in the liver, muscle, and pancreas and amplifying systemic insulin resistance. Consistent with this pathophysiology, measures of central adiposity such as waist circumference and imaging‑derived visceral fat area correlate more strongly with cardiometabolic outcomes, including type 2 diabetes, non‑alcoholic fatty liver disease, and cardiovascular events than BMI alone, underscoring that visceral fat is a distinct, high-risk organ rather than “just more fat} [3,4,5,6,7,8,9,10,11].

How The Gut Microbiome Talks to Fat

The gut microbiome exerts direct and indirect control over adipose tissue biology, influencing how fat cells are formed, how actively they release or store lipids, and how sensitive they remain to insulin. Multiple experimental and human studies show that microbial communities and their metabolites modulate adipogenesis, basal and catecholamine‑stimulated lipolysis, and whole‑body insulin sensitivity, partly through effects on inflammation and adipocyte signalling pathways. In obesity, dysbiosis is commonly characterised by shifts in the relative abundance of major phyla such as Firmicutes and Bacteroidetes, altered short‑chain fatty acid (SCFA) profiles, and increased intestinal permeability, which facilitate translocation of lipopolysaccharide and other microbial products into the circulation and promote low‑grade adipose inflammation. This chronic inflammatory state within adipose depots contributes to impaired insulin signalling, ectopic fat deposition, and progressive metabolic dysfunction [12,13,14,15,16,17,18,19,20].

SCFA-particularly acetate, propionate, and butyrate have emerged as key messengers in this gut-fat dialogue. These microbial metabolites signal through G‑protein–coupled receptors such as FFAR2 and FFAR3 on enteroendocrine cells, immune cells, hepatocytes, and adipocytes, triggering downstream pathways that influence GLP‑1 secretion, AMPK activation, substrate oxidation, and lipogenesis. Experimental and human data indicate that circulating SCFA concentrations are associated with fasting GLP‑1 levels, whole‑body lipolysis, and peripheral insulin sensitivity, supporting a mechanistic link between colonic fermentation and systemic metabolic control. Beyond the gut lumen, adipose tissue itself appears to host a distinct microbial signature, and perturbations in this local microbiome have been associated with heightened adipose inflammation and insulin resistance, reinforcing the concept of a bidirectional gut–adipose axis in obesity and related metabolic diseases [16,17,19,20,21,22].

Resistant Starch: Feeding The Inner Fat Burner

Resistant starch has emerged as a promising nutritional tool for targeting visceral adiposity, acting less as a simple “low‑calorie starch” and more as a microbiome‑mediated metabolic modulator. In controlled human trials, supplementation with type 2 resistant starch has been shown to reduce abdominal adiposity, including MRI‑quantified visceral fat, even when total energy intake is held constant. In a randomized, double‑blind, crossover feeding study, participants consumed either 40 g/day of high‑amylose RS2 or an energy‑matched control starch while receiving identical background diets; resistant starch led to significant reductions in fat mass, waist circumference, and visceral fat area over several weeks, whereas the control starch did not produce these changes. A larger crossover trial in adults with overweight or obesity similarly demonstrated that an 8‑week resistant starch phase reduced body weight, fat mass, waist circumference, and MRI‑measured visceral fat compared with a placebo starch, supporting a calorie‑independent effect on abdominal fat distribution [23,24,25].

Because the interventions were double‑blinded and the test and control starches were visually indistinguishable, behavioural and expectancy effects are unlikely to explain the findings, pointing instead to biological mechanisms centred on the gut microbiota. Mechanistic analyses from these and related studies show that resistant starch supplementation reshapes gut microbial composition (for example, enriching Bifidobacterium species), increases colonic fermentation and SCFA production, and favourably alters gut hormone profiles, including GLP‑1 and early‑phase insulin secretion. Parallel synbiotic trials in individuals with obesity report that combining targeted probiotics with prebiotic substrates reduces body fat percentage and waist circumference while increasing satiety hormones such as peptide YY and cholecystokinin and modifying bile acid and SCFA profiles, further supporting a microbiome‑hormone axis linking fermentable substrates to adiposity. Collectively, these data support a model in which resistant starch “feeds” specific microbial communities that enhance SCFA‑mediated signalling, improve gut barrier integrity, and promote insulin sensitivity and adipose tissue remodelling, thereby shrinking visceral fat depots beyond what would be expected from caloric dilution alone [23,26,27,28,29].

Practical Protocol: Shrink Visceral Fat via The Gut

Operationalizing a “gut‑first” approach to visceral fat reduction involves targeting the microbiota that generate beneficial SCFAs and anti‑inflammatory metabolites, while removing dietary and lifestyle drivers of dysbiosis and adipose inflammation. In practice, this means prioritizing resistant starches and fermentable fibers as foundational substrates, layering in strategies that support SCFA and GLP‑1 signalling, protecting the gut barrier, and integrating these with established metabolic tools such as fasting and resistance training [30,31,32,33,34,35].

A first pillar is systematic inclusion of resistant starch–rich foods and mixed fermentable fibers. Green or slightly unripe bananas, legumes, and certain whole grains naturally contain appreciable amounts of resistant starch, while cooking and cooling starchy foods such as potatoes and rice increases their RS3 content. A pragmatic protocol might combine food‑based sources with gradually titrated supplemental resistant starch or synbiotic formulations, beginning with low doses to reduce bloating and gas and adjusting upwards based on tolerance, while tracking waist circumference, fasting glucose, and subjective satiety as early response markers. In parallel, a diverse plant‑forward diet, emphasising a broad spectrum of fibers helps expand microbial taxa capable of producing acetate, propionate, and butyrate, reinforcing SCFA‑driven benefits on insulin sensitivity and adipose tissue function [23,24,31,35,36,37,38,39,40].

A second pillar is to leverage microbiome–hormone crosstalk. Fermentable fibers and resistant starches increase colonic SCFA production, which can enhance GLP‑1 release and improve glycaemic control; complementary data suggest that both probiotic interventions and GLP‑1 receptor agonists alter intestinal SCFA patterns and metabolic outcomes in type 2 diabetes. This convergence supports viewing prebiotics, probiotics, and GLP‑1–based therapies as acting along a shared gut–endocrine axis, with the potential to be combined in high‑risk individuals to optimise visceral fat reduction and cardiometabolic risk [31,35,41].

A third pillar is protection of  the gut barrier and attenuation of adipose inflammation. Western‑style diets, characterised by high fat, low fiber, and ultra‑processed foods, promote dysbiosis, increase gut permeability, and facilitate translocation of bacterial products such as lipopolysaccharide, which drive adipose macrophage activation and insulin resistance in experimental models and human studies. Clinical protocols should therefore emphasise adequate sleep, stress management, regular physical activity, and reduction of ultra‑processed foods and alcohol, not only for their independent metabolic benefits but also for their capacity to reduce endotoxemia and inflammatory signalling to visceral fat depots [31,33,35,42].

Finally, microbiome‑targeted nutrition is best framed as synergistic with, rather than substitutive for, classic metabolic interventions. Time‑restricted feeding and other intermittent fasting paradigms have been shown to reduce visceral adipose volume and improve adipose tissue inflammatory profiles, while resistance training preferentially preserves or increases lean mass during fat loss. Within this integrated model, caloric balance still constrains the magnitude of fat loss, but a healthier gut ecosystem may render visceral fat more metabolically labile, more “willing” to mobilise under energy deficit, thereby enhancing the cardiometabolic returns of standard diet and exercise prescriptions [24,31,32,34].

Responders, Non-Responders, and Personalization

Intervention trials with resistant starch and other microbiome‑directed strategies consistently show substantial inter‑individual variability in visceral fat and metabolic responses, even under tightly controlled dietary conditions. Baseline gut microbiome composition and host phenotype appear to be major determinants of this heterogeneity: multi‑omics analyses indicate that specific taxa and functional pathways at baseline can predict who will show greater improvements in hepatic steatosis and metabolic markers when exposed to resistant starch or similar prebiotic fibres. For example, recent work in metabolic dysfunction–associated steatotic liver disease found that individuals with microbiomes enriched in resistant‑starch degraders and SCFA producers responded more favourably to RS, whereas high baseline abundance of genera such as Prevotella was associated with blunted responses, likely by inhibiting key degraders. Complementary in vitro studies using microbiota from people with obesity show that SCFA production in response to different prebiotics is both donor‑ and substrate‑dependent, reinforcing that the same prebiotic can be highly efficacious in some microbiomes and relatively inert in others [43,44,45,46,47].

These findings provide a rationale for a “precision gut–visceral” framework in clinical practice and biohacking. At a minimum, individuals can be stratified by central adiposity and metabolic risk, using waist circumference, visceral fat imaging where available, fasting insulin, triglycerides, liver enzymes, and glycaemic indices, as well as by any accessible microbiome or SCFA readouts, to guide the choice and intensity of microbiome‑targeted interventions. In high‑risk phenotypes (e.g., marked visceral adiposity with insulin resistance or MASLD), clinicians might prioritise more aggressive fibre and resistant starch dosing, select prebiotics that align with the person’s microbial capacity for SCFA production, and add adjunctive tools such as GLP‑1 receptor agonists, which meta‑analyses show can significantly reduce visceral adipose tissue and hepatic fat content across diverse populations. Over time, iterative adjustment of fibre type and dose, synbiotic combinations, fasting regimens, and resistance training can be guided by changes in waist circumference, visceral fat on imaging, liver fat, and inflammatory biomarkers, operationalising a personalised, microbiome‑informed strategy rather than a one‑size‑fits‑all protocol for visceral fat reduction [43,48,49,50,51].

A Microbiome-First Lens for Visceral Fat

Visceral fat is not simply an inert reservoir of excess energy; it is an active immunometabolic organ whose behaviour is shaped, in part, by the composition and function of the gut microbiome. Framing visceral adiposity in this way moves the focus beyond weight or body mass index toward the quality, distribution, and inflammatory tone of adipose tissue. Dietary strategies that enrich for fermentable substrates, particularly resistant starches and mixed fibers that enhance short‑chain fatty acid production and gut hormone signalling, offer a means to modify this organ from the inside out, creating a metabolic milieu that favours visceral fat reduction and restoration of healthier adipose function rather than a narrow pursuit of “weight loss” alone.

For clinicians, researchers, and biohackers interested in longevity and metabolic resilience, this perspective supports a re‑ordering of therapeutic priorities. Instead of treating the gut as an afterthought, microbiome‑directed interventions become a logical first step, upon which caloric manipulation, physical activity, and, where appropriate, pharmacotherapy can be layered and titrated against objective markers such as waist circumference, visceral fat imaging, glycaemic indices, and inflammatory biomarkers. In practice, “feeding your inner fat burner” becomes less a narrative of individual willpower and more a systems‑level partnership with trillions of microbial co‑inhabitants, intentionally leveraged to remodel the most cardiometabolically hazardous fat depot in the body.

Reference

  1. Girard J, Lafontan M. Impact of visceral adipose tissue on liver metabolism and insulin resistance. Part II: Visceral adipose tissue production and liver metabolism. Diabetes & Metabolism. 2008 Nov;34(5):439–45.
  2. Kabir M, Catalano KJ, Ananthnarayan S, Kim SP, Van Citters GW, Dea MK, et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. American Journal of Physiology-Endocrinology and Metabolism. 2005 Feb;288(2):E454–61.
  3. Hanlon CL, Yuan L. Nonalcoholic Fatty Liver Disease: The Role of Visceral Adipose Tissue. Clinical Liver Disease. 2022 Jan 28;19(3):106–10.
  4. Gencer Sancar, Birkenfeld AL. The role of adipose tissue dysfunction in hepatic insulin resistance and T2D. Journal of Endocrinology [Internet]. 2024 Jul 1; Available from: https://joe.bioscientifica.com/view/journals/joe/262/3/JOE-24-0115.xml
  5. Francque S, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, et al. Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension. International Journal of Obesity. 2010 Jul 27;35(2):270–8.
  6. Sorisky A, Molgat ASD, Gagnon A. Macrophage-Induced Adipose Tissue Dysfunction and the Preadipocyte: Should I Stay (and Differentiate) or Should I Go? Advances in Nutrition [Internet]. 2013 Jan 4;4(1):67–75. Available from: https://www.sciencedirect.com/science/article/pii/S2161831322010900
  7. Surmi B, Hasty A. Macrophage infiltration into adipose tissue: initiation, propagation and remodeling. Future Lipidology [Internet]. 2008 Jan 1;3(5):545–56. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575346/
  8. UFO Themes. Usefulness of Measuring Both Body Mass Index and Waist Circumference for the Estimation of Visceral Adiposity and Related Cardiometabolic Risk Profile (from the INSPIRE ME IAA Study) [Internet]. Thoracic Key. 2016 [cited 2026 Mar 9]. Available from: https://thoracickey.com/usefulness-of-measuring-both-body-mass-index-and-waist-circumference-for-the-estimation-of-visceral-adiposity-and-related-cardiometabolic-risk-profile-from-the-inspire-me-iaa-study/
  9. Lee S, Kim Y, Han M. Influence of Waist Circumference Measurement Site on Visceral Fat and Metabolic Risk in Youth. Journal of Obesity & Metabolic Syndrome. 2022 Oct 24;
  10. Lindhorst A, Raulien N, Wieghofer P, Eilers J, Rossi FMV, Bechmann I, et al. Adipocyte death triggers a pro-inflammatory response and induces metabolic activation of resident macrophages. Cell Death & Disease. 2021 Jun;12(6).
  11. Christian AH, Mochari H, Mosca LJ. Waist Circumference, Body Mass Index, and Their Association With Cardiometabolic and Global Risk. Journal of the CardioMetabolic Syndrome. 2009 Dec;4(1):12–9.
  12. Jocken JWE, Reijnders D, Canfora EE, Boekschoten MV, Plat J, Goossens GH, et al. Effects of gut microbiota manipulation on ex vivo lipolysis in human abdominal subcutaneous adipocytes. Adipocyte. 2018 Apr 25;1–7.
  13. Iqbal M, Yu Q, Tang J, Xiang J. Unraveling the gut microbiota’s role in obesity: key metabolites, microbial species, and therapeutic insights. Kendall MM, editor. Journal of Bacteriology. 2025 Apr 4;
  14. Saad MJA, Santos A, Prada PO. Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance. Physiology [Internet]. 2016 Jul;31(4):283–93. Available from: https://journals.physiology.org/doi/full/10.1152/physiol.00041.2015
  15. Carvalho BM, Abdalla Saad MJ. Influence of Gut Microbiota on Subclinical Inflammation and Insulin Resistance. Mediators of Inflammation. 2013;2013:1–13.
  16. Virtue AT, McCright SJ, Wright JM, Jimenez MT, Mowel WK, Kotzin JJ, et al. The gut microbiota regulates white adipose tissue inflammation and obesity via a family of microRNAs. Science Translational Medicine [Internet]. 2019 Jun 12 [cited 2019 Oct 22];11(496):eaav1892. Available from: https://stm.sciencemag.org/content/11/496/eaav1892.full
  17. Wu D, Wang H, Xie L, Hu F. Cross-Talk Between Gut Microbiota and Adipose Tissues in Obesity and Related Metabolic Diseases. Frontiers in Endocrinology. 2022 Jul 5;13.
  18. Jeong S. Gut microbiota’s impact on obesity. Clinical and Experimental Pediatrics [Internet]. 2023 Jul 1 [cited 2026 Mar 9];66(7):294–5. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10331551/
  19. Castells-Nobau A, Moreno-Navarrete JM, de la Vega-Correa L, Puig I, Federici M, Sun J, et al. Multiomics of the intestine-liver-adipose axis in multiple studies unveils a consistent link of the gut microbiota and the antiviral response with systemic glucose metabolism. Gut [Internet]. 2025;74(2):229–45. Available from: https://pubmed.ncbi.nlm.nih.gov/39358003/
  20. Sanja Borozan, Fernandez CJ, Adnan Samee, Pappachan JM. Gut–Adipose Tissue Axis and Metabolic Health. Current Issues in Molecular Biology [Internet]. 2025 Jun 6;47(6):424–4. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12191825/
  21. Müller M, Hernández MAG, Goossens GH, Reijnders D, Holst JJ, Jocken JWE, et al. Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans. Scientific Reports [Internet]. 2019 Aug 29;9(1):12515. Available from: https://www.nature.com/articles/s41598-019-48775-0
  22. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, et al. Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein-Coupled Receptor FFAR2. Diabetes. 2011 Dec 21;61(2):364–71.
  23. Zhang L, Ouyang Y, Li H, Shen L, Ni Y, Fang Q, et al. Metabolic phenotypes and the gut microbiota in response to dietary resistant starch type 2 in normal-weight subjects: a randomized crossover trial. Scientific Reports. 2019 Mar 20;9(1).
  24. Li H, Zhang L, Li J, Wu Q, Qian L, He J, et al. Resistant starch intake facilitates weight loss in humans by reshaping the gut microbiota. Nature Metabolism [Internet]. 2024 Feb 26;1–20. Available from: https://www.nature.com/articles/s42255-024-00988-y#MOESM1
  25. Feikes M. Resistant Starch Intake Facilitates Weight Loss in Humans by Reshaping the Gut Microbiota – Global Prebiotic Association [Internet]. Global Prebiotic Association. 2025 [cited 2026 Mar 9]. Available from: https://prebioticassociation.org/resistant-starch-intake-facilitates-weight-loss-in-humans-by-reshaping-the-gut-microbiota/
  26. Norwitz N. Shrink Visceral Fat by Feeding Your Microbiome [Internet]. Substack.com. StayCurious Metabolism; 2026 [cited 2026 Mar 9]. Available from: https://staycuriousmetabolism.substack.com/p/shrink-visceral-fat-by-feeding-your
  27. Lin CW, Zou HB, Chen RA, Li CS, Lin CY, Hsu CC. A synbiotic supplement reduces body fat and increases GLP-1 secretion in a pilot clinical study. Journal of Functional Foods [Internet]. 2026 Jan 20;137:107171. Available from: https://www.sciencedirect.com/science/article/pii/S1756464626000216
  28. Higgins JA. Resistant Starch and Energy Balance: Impact on Weight Loss and Maintenance. Critical Reviews in Food Science and Nutrition. 2014 Jan;54(9):1158–66.
  29. Niu X, Zhang Q, Liu J, Zhao Y, Shang N, Li S, et al. Effect of synbiotic supplementation on obesity and gut microbiota in obese adults: a double-blind randomized controlled trial. Frontiers in Nutrition [Internet]. 2024 Nov 27;11. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11633458/
  30. Chen Z, Liang N, Zhang H, Li H, Guo J, Zhang Y, et al. Resistant starch and the gut microbiome: Exploring beneficial interactions and dietary impacts. Food Chemistry: X [Internet]. 2024 Mar 30;21:101118. Available from: https://www.sciencedirect.com/science/article/pii/S2590157524000051
  31. Priyadarshini M, Khan MW, Xu K, Yeh J, Wicksteed B, Layden B. Fiber Diet-Mediated Increases in Short Chain Fatty Acids Alleviate Western Diet Induced Metabolic Dysfunction. Current Developments in Nutrition. 2021 Jun;5:1175.
  32. Keenan S, Cooke MB, Belski R. The Effects of Intermittent Fasting Combined with Resistance Training on Lean Body Mass: A Systematic Review of Human Studies. Nutrients. 2020 Aug 6;12(8):2349.
  33. Tran HQ, Bretin A, Adeshirlarijaney A, Yeoh BS, Vijay-Kumar M, Zou J, et al. “Western Diet”-Induced Adipose Inflammation Requires a Complex Gut Microbiota. Cellular and Molecular Gastroenterology and Hepatology. 2020;9(2):313–33.
  34. Bahadoran Z, Mirmiran P, Kashfi K, Ghasemi A. Effects of time-restricted feeding (TRF)-model of intermittent fasting on adipose organ: a narrative review. Eating and Weight Disorders – Studies on Anorexia, Bulimia and Obesity. 2024 Dec 24;29(1).
  35. Ahmad S, Assaf M, Thomas B, Ibrahim H, Gowthami Muppuri, Chand P, et al. Fecal Short-Chain Fatty Acids (SCFAs) and Their Role in Metabolic Disorders: A Systematic Review. Cureus [Internet]. 2025 Sep 4;17(9):e91579–9. Available from: https://www.cureus.com/articles/402048-fecal-short-chain-fatty-acids-scfas-and-their-role-in-metabolic-disorders-a-systematic-review#
  36. Chen Z, Liang N, Zhang H, Li H, Guo J, Zhang Y, et al. Resistant starch and the gut microbiome: Exploring beneficial interactions and dietary impacts. Food Chemistry: X [Internet]. 2024 Mar 30;21:101118. Available from: https://www.sciencedirect.com/science/article/pii/S2590157524000051
  37. McKinney C. What is Resistant Starch? [Internet]. The Johns Hopkins Patient Guide to Diabetes. 2018. Available from: https://hopkinsdiabetesinfo.org/what-is-resistant-starch/
  38. 9 Foods That Are High in Resistant Starch [Internet]. Healthline. 2016. Available from: https://www.healthline.com/nutrition/9-foods-high-in-resistant-starch
  39. Tinsley G. Cooling Some Foods After Cooking Increases Their Resistant Starch [Internet]. Healthline. 2017. Available from: https://www.healthline.com/nutrition/cooling-resistant-starch
  40. Improve Your Gut Health with Resistant Starch [Internet]. Uhhospitals.org. University Hospitals; 2025. Available from: https://www.uhhospitals.org/blog/articles/2025/01/improve-your-gut-health-with-resistant-starch
  41. Min Q, Wang Y, Jin T, Zhu L, Wu X, Li Y, et al. Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus. Frontiers in Endocrinology. 2022 Jun 30;13.
  42. Ding S, Chi MM, Scull BP, Rigby R, Schwerbrock NMJ, Magness S, et al. High-Fat Diet: Bacteria Interactions Promote Intestinal Inflammation Which Precedes and Correlates with Obesity and Insulin Resistance in Mouse. Gaetani S, editor. PLoS ONE. 2010 Aug 16;5(8):e12191.
  43. Long X, Wang H, Lu Y, Gao X, Xiao Y, Zhang M, et al. Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLD. Cell metabolism [Internet]. 2025 Feb;37(12):2342-2361.e9. Available from: https://pubmed.ncbi.nlm.nih.gov/41270737/
  44. Venkataraman A, Sieber JR, Schmidt AW, Waldron C, Theis KR, Schmidt TM. Variable responses of human microbiomes to dietary supplementation with resistant starch. Microbiome. 2016 Jun 29;4(1).
  45. Bendiks ZA, Knudsen KEB, Keenan MJ, Marco ML. Conserved and variable responses of the gut microbiome to resistant starch type 2. Nutrition Research. 2020 May;77:12–28.
  46. Holmes ZC, Silverman JD, Dressman HK, Wei Z, Dallow EP, Armstrong SC, et al. Short-Chain Fatty Acid Production by Gut Microbiota from Children with Obesity Differs According to Prebiotic Choice and Bacterial Community Composition. mBio [Internet]. 2020 Aug 11;11(4):e00914-20. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439474/
  47. Maier TV, Lucio M, Lee LH, VerBerkmoes NC, Brislawn CJ, Bernhardt J, et al. Impact of Dietary Resistant Starch on the Human Gut Microbiome, Metaproteome, and Metabolome. mBio [Internet]. 2017 Oct 17;8(5). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646248/
  48. Le Roy CI, Bowyer RCE, Castillo-Fernandez JE, Pallister T, Menni C, Steves CJ, et al. Dissecting the role of the gut microbiota and diet on visceral fat mass accumulation. Scientific Reports. 2019 Jul 5;9(1).
  49. Liao C, Liang X, Zhang X, Li YQ. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis. PLOS ONE. 2023 Aug 24;18(8):e0289616–6.
  50. Eslick S, Williams EJ, Berthon BS, Wright T, Karihaloo C, Gately M, et al. Weight Loss and Short-Chain Fatty Acids Reduce Systemic Inflammation in Monocytes and Adipose Tissue Macrophages from Obese Subjects. Nutrients. 2022 Feb 11;14(4):765.
  51. Voruganti VS. Precision Nutrition: Recent Advances in Obesity. Physiology. 2023 Jan 1;38(1):42–50.

Discover more from A1C Almanac

Subscribe now to keep reading and get access to the full archive.

Continue reading